CG Oncology: Ambaw Bellete plans 5,789-share sale

CG Oncology, Inc. (CGON) has a notice of proposed resale of its common stock under Rule 144 filed on behalf of Ambaw Bellete.

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) has a notice of proposed resale of its common stock under Rule 144 filed on behalf of Ambaw Bellete. The filing lists an arrangement through Morgan Stanley Smith Barney LLC – Executive Financial Services for the potential sale of 5,789 shares of common stock, with a closing date referenced as August 27, 2026.

The notice also lists multiple prior sales of CG Oncology common stock by Ambaw Bellete over the past three months, each with specific share amounts and total dollar values, indicating ongoing secondary market selling activity by this holder. These transactions relate to existing shares and a stock option exercise, rather than a new issuance by CG Oncology.

Key Figures

Shares registered for proposed sale: 5,789 shares of common stock Recent sale on 08/25/2026: 10,551 shares; $839,338.38 total value Recent sale on 08/19/2026: 100,000 shares; $7,954,105.00 total value +3 more

6 metrics

Shares registered for proposed sale 5,789 shares of common stock Listed under Securities To Be Sold with a stock option exercise, dated 08/27/2026

Recent sale on 08/25/2026 10,551 shares; $839,338.38 total value Common stock sale by Ambaw Bellete during the past 3 months

Recent sale on 08/19/2026 100,000 shares; $7,954,105.00 total value Common stock sale by Ambaw Bellete during the past 3 months

Recent sale on 08/17/2026 52,438 shares; $4,034,894.35 total value Common stock sale by Ambaw Bellete during the past 3 months

Recent sale on 08/11/2026 50,000 shares; $3,810,255.00 total value Common stock sale by Ambaw Bellete during the past 3 months

Recent sale on 07/28/2026 50,000 shares; $3,625,195.00 total value Common stock sale by Ambaw Bellete during the past 3 months

Key Terms

Rule 144, Securities To Be Sold, Stock Option Exercise, Executive Financial Services, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Securities To Be Sold regulatory

"144: Securities To Be Sold Common | 08/27/2026 | Stock Option Exercise"

Stock Option Exercise financial

"Common | 08/27/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Executive Financial Services financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

Common financial

"Common | 08/27/2026 | Stock Option Exercise | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for CGON disclose?

The Form 144 filing discloses that Ambaw Bellete plans a potential sale of 5,789 shares of CG Oncology, Inc. common stock through Morgan Stanley Smith Barney LLC, tied to a stock option exercise, with a closing date referenced as August 27, 2026.

Is CG Oncology, Inc. (CGON) issuing new shares in this Form 144?

No. The Form 144 relates to the resale of existing common shares for the account of Ambaw Bellete, including shares associated with a stock option exercise. The notice concerns secondary market sales, not a new capital-raising issuance by CG Oncology, Inc.

How many CGON shares are proposed to be sold under this new Form 144?

The notice lists 5,789 shares of CG Oncology, Inc. common stock under “Securities To Be Sold,” associated with a stock option exercise and a referenced closing date of August 27, 2026.

What recent CGON share sales by Ambaw Bellete are reported in the past 3 months?

The filing lists multiple sales of CG Oncology common stock by Ambaw Bellete between July 15, 2026 and August 25, 2026, each showing the trade date, number of shares, and total dollar value for those completed transactions.

On which market is CG Oncology, Inc. common stock traded according to this filing?

The securities information section states that CG Oncology, Inc. common stock is traded on NASDAQ, and the Form 144 relates to potential sales of that NASDAQ-listed common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 05:08 PM EDT Accepted by SEC EDGAR 08/27/2026 - 05:07 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002007090
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CG ONCOLOGY, INC.
SEC File Number	001-41925
Address of Issuer	3000 Pegasus Park Drive SUITE 1640 Dallas TEXAS 75247
Phone	(949) 409-3700
Name of Person for Whose Account the Securities are To Be Sold	AMBAW BELLETE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5789	459560.92	88640375	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/27/2026	Stock Option Exercise	Issuer			5789	08/27/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/25/2026	10551	839338.38
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/24/2026	5762	458185.02
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/19/2026	100000	7954105.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/17/2026	52438	4034894.35
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/14/2026	19364	1452635.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/13/2026	25989	1973970.86
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/12/2026	32137	2526514.53
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/11/2026	50000	3810255.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/10/2026	50000	3770580.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/07/2026	9250	696062.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/06/2026	75000	5672212.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/05/2026	25000	1837500.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/29/2026	4303	316270.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/28/2026	50000	3625195.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/27/2026	50000	3627995.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/23/2026	50000	3588620.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/15/2026	52438	3816007.65

144: Remarks and Signature

Remarks
Date of Notice	08/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ambaw Bellete
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)